B · Normal
[Inflammatory disease biotechnology company Rezera postpones US$200 million IPO in the United States] November 16th, the biotechnology company Rezera, which develops oral NLRP3 inflammation inhibitors and has advanced its pipeline to Phase III clinical trials, said last Thursday that it would postpone its listing. The company had previously filed for an IPO, planning to issue 16.7 million shares with an issuance range of US$11-13, raising US$200 million. As a new investor and its related parties, the pharmaceutical company GlaxoSmithKline has promised to subscribe for up to US$25 million, accounting for 13% of the issuance size.
Comments